Additional file 1: Figure S1. of Model selection criteria for dynamic brain PET studies

Typical whole brain gray matter TACs of all the six brain PET radiotracers. (TIFF 43 kb

Additional file 1: of Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLC

Supplementary data. Table S1. Parent fractions (%). Table S2. Whole blood SUV. Table S3. Tumor [11C]erlotinib V T and K1 values. Table S4. Tumor [15O]H2O flow values. Table S5. SUV and TBR values (unitless). (DOC 170 kb

Additional file 1: of Purinergic receptors P2Y12R and P2X7R: potential targets for PET imaging of microglia phenotypes in multiple sclerosis

Includes supplementary figures and tables to support the data presented in the main manuscript. (DOCX 14306 kb

Additional file 1: of Quantification of O-(2-[18F]fluoroethyl)-L-tyrosine kinetics in glioma

Details MR sequences. Details blood sample measurements. Table S1. Patient details. Figure S1. Transaxial views of the tumours on 20–40 min standardised uptake value maps of [18F]FET. Figure S2. Scatter (A) and Bland-Altman plot (B) of volume of distribution, VT, calculated with the 1T2kVb model versus the 2T4kVb model. Shaded areas are 95% confidence intervals. Figure S3. Scatterplot of volume of distribution (VT) versus cerebral blood flow (CBF) (A). The same plot with each patient indicated separately, connecting low, medium and high VOIs with lines (B). CBF data was not available for patient 6. Figure S4. Scatterplot of K1 versus cerebral blood flow (CBF) (A). The same plot with each patient indicated separately, connecting low, medium and high VOIs with lines (B). CBF data was not available for patient 6. Figure S5. Scatterplot of extraction versus cerebral blood flow (CBF). Figure S6. Scatterplots of simplified reference tissue model estimates of binding potential (BPND) (A) and K1-ratio (R1) (B) against the cerebral blood flow ratio (CBF-ratio). Figure S7. Scatter plot of SUV20–40 versus the volume of distribution (VT) calculated with the 2T4kVb model. (PDF 237 kb

Additional file 2: of Quantification of O-(2-[18F]fluoroethyl)-L-tyrosine kinetics in glioma

Patient information, TACs, AIFs. (XLSX 443 kb